All News

Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.

Cobenfy, previously KarXT, is the first new agent with a novel mechanism of action for schizophrenia in more than 50 years, according to BMS.

Your daily dose of the clinical news you may have missed.

A 2-year-old child has had a low-grade fever for 4 days and a swelling has developed behind the left ear. She just recovered from a URI. What's your diagnosis?

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

Your daily dose of the clinical news you may have missed.

The decline in cancer diagnoses during the COVID-19 shutdown in 2020 did not lead to an expected compensatory increase in diagnoses in 2021, according to NCI researchers.

Among adolescents and adults with moderate-to-severe AD, more than 80% achieved sustained disease control, the majority not requiring topical or systemic rescue medication.

Roflumilast cream 0.15% was associated with consistent and meaningful improvements in AD clearance and itch reduction, according to new data.

A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.

Your daily dose of the clinical news you may have missed.

How are you managing your patients with resistant or refractory hypertension? How do your strategies align with current guidelines? Try these 9 questions and find out.

JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.

Delgocitinib specifically inhibits activation of JAK-STAT signaling in chronic hand eczema and would be an option for people unable to use topical corticosteroids.

Your daily dose of the clinical news you may have missed.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

The AI-based point-of-care device outperformed clinician standard of care for sensitivity (90% vs 40%) and had a negative predictive value of 98.9%

Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.